Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 6/2013

01.12.2013 | CENTRAL NERVOUS SYSTEM (J LYONS, SECTION EDITOR)

Central Nervous System Infections in Travelers

verfasst von: H. L. Kirsch, K. T. Thakur, G. L. Birbeck

Erschienen in: Current Infectious Disease Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

International travelers commonly contract infections while abroad, many of which are primary neurological diseases or have potential neurological sequelae. The implications of these neuroinfectious diseases extend beyond the individual, since returning travelers may contribute to the spread of infection in novel areas. In this review, we discuss signs, symptoms, treatments, and prophylaxes for these infections, as well as emerging trends with regard to neuroinfectious diseases of the returning traveler.
Literatur
1.
•• Leder K, Torresi J, Libman MD, et al. GeoSentinel surveillance of illness in returned travelers, 2007–2011. Ann intern med. 2013;158(6):456–68. Using data from approximately 42,000 travelers presenting to travel or tropical medicine clinics, this GeoSentinel study elucidates patterns of disease contracted by travelers to numerous abroad sites.
2.
Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl j med. 2005;353(9):924–32.PubMed
3.
Chen LH, Wilson ME. Dengue and chikungunya infections in travelers. Curr opin infect dis. 2010;23(5):438–44.PubMed
4.
Jelinek T. Dengue fever in international travelers. Clin infect dis off publ Infect Dis Soc Am. 2000;31(1):144–7.
5.
Tuiskunen A, Hjertqvist M, Vene S, Lundkvist A. Dengue fever in returned Swedish travelers from Thailand. Infect ecol epidemiol. 2011;1.
6.
Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J infect dis. 2007;195(8):1089–96.PubMed
7.
Streit JA, Yang M, Cavanaugh JE, Polgreen PM. Upward trend in dengue incidence among hospitalized patients, United States. Emerg infec dis. 2011;17(5):914–6.
8.
Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum vaccines. 2010;6(9).
9.
Chastel C. Eventual role of asymptomatic cases of dengue for the introduction and spread of dengue viruses in non-endemic regions. Front physiol. 2012;3:70.PubMed
10.
Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet. 2000;355(9209):1053–9.PubMed
11.
Misra UK, Kalita J, Syam UK, Dhole TN. Neurological manifestations of dengue virus infection. J neurol sci. 2006;244(1–2):117–22.PubMed
12.
Wasay M, Channa R, Jumani M, Shabbir G, Azeemuddin M, Zafar A. Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin neurol neurosurg. 2008;110(6):635–40.PubMed
13.
Larik A, Chiong Y, Lee LC, Ng YS. Longitudinally extensive transverse myelitis associated with dengue fever. BMJ case rep. 2012;2012.
14.
Gutch M, Agarwal A, Amar A. Hypokalemic quadriparesis: an unusual manifestation of dengue fever. J nat sci biol med. 2012;3(1):81–3.PubMed
15.
Ratnayake EC, Shivanthan C, Wijesiriwardena BC. Diaphragmatic paralysis: a rare consequence of dengue fever. BMC infect dis. 2012;12:46.PubMed
16.
Huhtamo E, Hasu E, Uzcategui NY, et al. Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. J clin virol off publ Pan Am Soc Clin Virol. 2010;47(1):49–53.
17.
Moi ML, Ujiie M, Takasaki T, Kurane I. Dengue virus infection in travellers returning from Benin to France, July - August, 2010. Euro surveill bull Europeen sur les maladies transmissibles = Eur commun dis bull. 2010;15(39):19674.
18.
Moi ML, Omatsu T, Tajima S, et al. Detection of dengue virus nonstructural protein 1 (NS1) by using ELISA as a useful laboratory diagnostic method for dengue virus infection of international travelers. J travel med. 2013;20(3):185–93.PubMed
19.
Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67.PubMed
20.
Thomas SJ, Eckels KH, Carletti I, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am j trop med hygiene. 2013;88(1):73–88.
21.
Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J infect dis. 2013;207(5):700–8.PubMed
22.
Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. J travel med. 2007;14(4):259–68.PubMed
23.
Fischer M, Lindsey N, Staples JE, Hills S, Centers for Disease C, Prevention. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm rep Morb mortal wkly rep Recomm rep Cent Dis Control. 2010;59(RR-1):1–27.
24.
Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J travel med. 2009;16(3):217–9.PubMed
25.
Hatz C. Editorial commentary: boosting Japanese encephalitis vaccine. Clin infect dis off publ Infect Dis Soc Am. 2012;55(6):835–6.
26.
Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973–2008. Am j trop med hyg. 2010;82(5):930–6.PubMed
27.
Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J neurol neurosurg psychiatr. 2000;68(4):405–15.PubMed
28.
Ghosh D, Basu A. Japanese encephalitis-a pathological and clinical perspective. PLoS negl trop dis. 2009;3(9):e437.PubMed
29.
Kalita J, Misra UK. Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis. J neurol sci. 2000;174(1):3–8.PubMed
30.
Verma R. MRI features of Japanese encephalitis. BMJ case rep. 2012;2012.
31.
Duffy MR, Reed C, Edelson PJ, et al. A survey of US travelers to Asia to assess compliance with recommendations for the use of Japanese encephalitis vaccine. J travel med. 2013;20(3):165–70.PubMed
32.
Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS pathog. 2007;3(12):e201.PubMed
33.
Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet. 2012;379(9816):662–71.PubMed
34.
Zayed A, Awash AA, Esmail MA, et al. Detection of Chikungunya virus in Aedes aegypti during 2011 outbreak in Al Hodayda, Yemen. Acta trop. 2012;123(1):62–6.PubMed
35.
Chowdhury FI, Kabir A, Das A, Mukerrama SM, Masud S. Chikungunya fever: an emerging threat to Bangladesh. J Med. 2012;13(1):60–4.
36.
Kularatne SA, Weerasinghe SC, Gihan C, et al. Epidemiology, clinical manifestations, and long-term outcomes of a major outbreak of chikungunya in a hamlet in sri lanka, in 2007: a longitudinal cohort study. J trop med. 2012;2012:639178.PubMed
37.
Wu D, Wu J, Zhang Q, et al. Chikungunya outbreak in Guangdong Province, China, 2010. Emerg infect dis. 2012;18(3):493–5.PubMed
38.
Centers for Disease C, Prevention. Chikungunya outbreak--Cambodia, February-March 2012. MMWR Morb mortal wkly rep. 2012;61:737–40.
39.
Gibney KB, Fischer M, Prince HE, et al. Chikungunya fever in the United States: a fifteen year review of cases. Clin infect dis off publ Infect Dis Soc Am. 2011;52(5):e121–6.
40.
Parola P, de Lamballerie X, Jourdan J, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg infect dis. 2006;12(10):1493–9.PubMed
41.
Jaffar-Bandjee MC, Das T, Hoarau JJ, et al. Chikungunya virus takes centre stage in virally induced arthritis: possible cellular and molecular mechanisms to pathogenesis. Microbes infect Inst Pasteur. 2009;11(14–15):1206–18.
42.
Moro ML, Grilli E, Corvetta A, et al. Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study. J infect. 2012;65(2):165–72.PubMed
43.
Das T, Jaffar-Bandjee MC, Hoarau JJ, et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog neurobiol. 2010;91(2):121–9.PubMed
44.
Lemant J, Boisson V, Winer A, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005–2006. Crit care med. 2008;36(9):2536–41.PubMed
45.
Schilte C, Staikovsky F, Couderc T, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS negl trop dis. 2013;7(3):e2137.PubMed
46.
Tournebize P, Charlin C, Lagrange M. Neurological manifestations in Chikungunya: about 23 cases collected in Reunion Island. Rev neurol. 2009;165(1):48–51.PubMed
47.
Gasque P. Chikungunya Virus Infection. In: Jackson AC, editor. Viral Infections of the Human Nervous System. Berlin: Springer; 2012.
48.
Kee AC, Yang S, Tambyah P. Atypical chikungunya virus infections in immunocompromised patients. Emerg infect dis. 2010;16(6):1038–40.PubMed
49.
Hatz CF, Kuenzli E, Funk M. Rabies: relevance, prevention, and management in travel medicine. Infect dis clin N Am. 2012;26(3):739–53.
50.
Gautret P, Adehossi E, Soula G, et al. Rabies exposure in international travelers: do we miss the target? Int j infect dis IJID off publ Int Soc Infect Dis. 2010;14(3):e243–6.
51.
Malerczyk C, Detora L, Gniel D. Imported human rabies cases in europe, the United States, and Japan, 1990 to 2010. J travel med. 2011;18(6):402–7.PubMed
52.
Hemachudha T, Laothamatas J, Rupprecht CE. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet neurol. 2002;1(2):101–9.PubMed
53.
Warrell MJ. Intradermal Rabies Vaccination: The Evolution and Future of Pre- and Post-exposure Prophylaxis. In: Teunissen MBM, editor. Intradermal Immunization. Berlin: Springer; 2012. p. 139–57.
54.
Wongsaroj P, Udomchaisakul P, Tepsumethanon S, Khawplod P, Tantawichien T. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis. Vaccine. 2013;31(13):1748–51.PubMed
55.
Gautret P, Parola P. Rabies vaccination for international travelers. Vaccine. 2012;30(2):126–33.PubMed
56.
Meslin FX. Rabies as a traveler's risk, especially in high-endemicity areas. J travel med. 2005;12 Suppl 1:S30–40.PubMed
57.
Sakai H, Harun FM, Yamamoto N, Yuki N. Contamination with gangliosides in brain-derived rabies vaccine may trigger Guillain–Barre syndrome. J neurol neurosurg psychiatr. 2012;83(4):467–9.PubMed
58.
Sudarshan MK, Mahendra BJ, Madhusudana SN, et al. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J commun dis. 2006;38(1):32–9.PubMed
59.
Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83(5):360–8.PubMed
60.
Ayele W, Fekadu M, Zewdie B, et al. Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. Ethiop med j. 2001;39(4):313–21.PubMed
61.
Wilde H, Tipkong P, Khawplod P. Economic issues in postexposure rabies treatment. J travel med. 1999;6(4):238–42.PubMed
62.
Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 6/24/ 2009;27, Supplement 2(0):B13-B19.
63.
Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int j infect dis IJID off publ Int Soc Infect Dis. 2010;14(7):e553–9.
64.
•• Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin infect dis off publ Infect Dis Soc Am. 2013;56(3):354–63. This article shows that mass vaccination against serogroup A Neisseria meningitidis (NmA) in Burkina Faso eliminated NmA carriage in vaccinated districts and induced a herd-immunity effect against the pathogen.
65.
Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet infect dis. 2007;7(12):797–803.PubMed
66.
Dakar discussion group on priorities for research on epidemic meningococcal disease in A, Altmann D, Aseffa A, et al. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013;31(11):1453–1457.
67.
Bilukha OO, Rosenstein N, National Center for Infectious Diseases CfDC, Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm rep Morb mortal wkly rep Recomm rep Cent Dis Control. 2005;54(RR-7):1–21.
68.
Wilder-Smith A. Meningococcal disease: risk for international travellers and vaccine strategies. Travel med infect dis. 2008;6(4):182–6.PubMed
69.
Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcen P, Unemo M. Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives. Antimicrob agents chemother. 2009;53(4):1561–6.PubMed
70.
Leimkugel J, Adams Forgor A, Gagneux S, et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J infect dis. 2005;192(2):192–9.PubMed
71.
Standardized treatment of bacterial meningitis in Africa in epidemic and non epidemic situations. 2007.
72.
van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693–702.PubMed
73.
Thakur K, Zunt J. Neurologic parasitic infections in immigrants and travelers. Semin neurol. 2011;31(3):231–44.PubMed
74.
Del Brutto OH. Neurocysticercosis among international travelers to disease-endemic areas. J travel med. 2012;19(2):112–7.PubMed
75.
Leshem E, Kliers I, Bakon M, Gomori M, Karplus R, Schwartz E. Neurocysticercosis in travelers: a nation-wide study in Israel. J travel med. 2011;18(3):191–7.PubMed
76.
Del Brutto OH, Nash TE, Garcia HH. Cysticerci-related single parenchymal brain enhancing lesions in non-endemic countries. J neurol sci. 2012;319(1–2):32–6.PubMed
77.
Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology. 2013;80(2):152–62.PubMed
78.
Simarro PP, Franco JR, Cecchi G, et al. Human African trypanosomiasis in non-endemic countries (2000–2010). J travel med. 2012;19(1):44–53.PubMed
79.
Blum JA, Neumayr AL, Hatz CF. Human African trypanosomiasis in endemic populations and travellers. Eur j clin microbiol infect dis off publ Eur Soc Clin Microbiol. 2012;31(6):905–13.
80.
Migchelsen SJ, Buscher P, Hoepelman AI, Schallig HD, Adams ER. Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. Int j infect dis IJID off publ Int Soc Infect Dis. 2011;15(8):e517–24.
81.
Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS negl trop dis. 2011;5(11):e1358.PubMed
82.
Kennedy PG. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet neurol. 2013;12(2):186–94.PubMed
83.
Diaz JH. Recognizing and reducing the risks of Chagas disease (American trypanosomiasis) in travelers. J travel med. 2008;15(3):184–95.PubMed
84.
Pereira KS, Schmidt FL, Barbosa RL, et al. Transmission of chagas disease (American trypanosomiasis) by food. Adv food nutr res. 2010;59:63–85.PubMed
85.
Oliveira-Filho J, Viana LC, Vieira-De-Melo RM, et al. Chagas disease is an independent risk factor for stroke - Baseline characteristics of a Chagas disease cohort. Stroke. 2005;36(9):2015–7.PubMed
86.
Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta trop. 2010;115(1–2):22–7.PubMed
87.
Loutan L. Malaria: still a threat to travellers. Int j antimicrob agents. 2003;21(2):158–63.PubMed
88.
Kain KC, Keystone JS. Malaria in travelers. Epidemiology, disease, and prevention. Infect dis clin N Am. 1998;12(2):267–84.
89.
Strickland GT. Fever in the returned traveler. Med clin N Am. 1992;76(6):1375–92.PubMed
90.
O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin infect dis off publ Infect Dis Soc Am. 2001;33(5):603–9.
91.
Filler S, Causer LM, Newman RD, et al. Malaria surveillance–United States, 2001. Morb mortal wkly rep Surveill summ. 2003;52(5):1–14.
92.
Mali S, Kachur SP, Arguin PM, et al. Malaria surveillance–United States, 2010. Morb mortal wkly rep Surveill summ. 2012;61(2):1–17.
93.
World Malaria Report 2011. Geneva: World Health Organization;2011.
94.
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans Roy Soc Trop Med Hyg. 2000;94 Suppl 1:S1-90.
95.
Varney NR, Roberts RJ, Springer JA, Connell SK, Wood PS. Neuropsychiatric sequelae of cerebral malaria in Vietnam veterans. J nerv ment dis. 1997;185(11):695–703.PubMed
96.
Dugbartey AT, Dugbartey MT, Apedo MY. Delayed neuropsychiatric effects of malaria in Ghana. J nerv ment dis. 1998;186(3):183–6.PubMed
97.
Roze E, Thiebaut MM, Mazevet D, et al. Neurologic sequelae after severe falciparum malaria in adult travelers. Eur neurol. 2001;46(4):192–7.PubMed
98.
Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet. 1996;348(9032):917–21.PubMed
99.
Gilles HM. Management of Severe and Complicated Malaria: A Practical Handbook. Geneva: World Health Organization; 1991.
100.
Praveen KAS, Subrahmanyam DKS. A rare cause of Guillain-Barre syndrome. Int J Nutr Pharm Neurol Dis. 2011;1(2):204–5.
101.
Sokrab TE, Eltahir A, Idris MN, Hamid M. Guillain-Barre syndrome following acute falciparum malaria. Neurology. 2002;59(8):1281–3.PubMed
102.
Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet neurol. 2005;4(12):827–40.PubMed
103.
Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin microbiol rev. 2008;21(3):466–72.PubMed
104.
Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25.PubMed
105.
Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta trop. 2000;77(1):41–51.PubMed
106.
Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl j med. 2002;346(16):1212–20.PubMed
107.
Control CfD. Schistosomiasis FAQs. 2012. Accessed July 12, 2013, 2013.
108.
Pittella JEH. Neuroschistosomiasis. In: Misra UD, Kalita J, Shakir RA, editors. Tropical Neurology. Georgetown: Landes Bioscience; 2003. p. 300–24.
109.
Pittella JE. Neuroschistosomiasis. Brain pathol. 1997;7(1):649–62.PubMed
110.
Pittella JEH. The Relation between Involvement of the Central-Nervous-System in Schistosomiasis-Mansoni and the Clinical Forms of the Parasitosis - a Review. J Trop Med Hyg. 1991;94(1):15–21.PubMed
111.
McManus DP, Li Y, Gray DJ, Ross AG. Conquering 'snail fever': schistosomiasis and its control in China. Expert rev anti-infect ther. 2009;7(4):473–85.PubMed
112.
Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol rev. 2004;201:156–67.PubMed
113.
Ferrari TC. Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Medicine. 1999;78(3):176–90.PubMed
114.
Clerinx J, van Gompel A, Lynen L, Ceulemans B. Early neuroschistosomiasis complicating Katayama syndrome. Emerg infect dis. 2006;12(9):1465–6.PubMed
115.
Ferrari TCA, Moreira PRR, Cunha AS. Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment. Acta trop. 2008;108(2–3):89–97.PubMed
116.
Carod-Artal FJ. Neurological complications of Schistosoma infection. Trans R Soc Trop Med Hyg. 2008;102(2):107–16.PubMed
117.
Carod-Artal FJ. Neuroschistosomiasis. Expert rev anti-infective ther. 2010;8(11):1307–18.
118.
Houdon L, Flodrops H, Rocaboy M, et al. Two Patients With Imported Acute Neuroschistosomiasis Due to Schistosoma mansoni. J travel med. 2010;17(4):274–7.PubMed
119.
Jaureguiberry S, Ansart S, Perez L, Danis M, Bricaire F, Caumes E. Acute neuroschistosomiasis: two cases associated with cerebral vasculitis. Am j trop med hyg. 2007;76(5):964–6.PubMed
120.
Sarazin M, Caumes E, Cohen A, Amarenco P. Multiple microembolic borderzone brain infarctions and endomyocardial fibrosis in idiopathic hypereosinophilic syndrome and in Schistosoma mansoni infestation. J neurol neurosurg psychiatr. 2004;75(2):305–7.PubMed
121.
Devine MJ, Wilkinson PA, Doherty JF, Jarman PR. Neuroschistosomiasis presenting as brainstem encephalitis. Neurology. 2008;70(23):2262–4.PubMed
122.
Hayashi M. Clinical features of cerebral schistosomiasis, especially in cerebral and hepatosplenomegalic type. Parasitol Int. 2003;52(4):375–83.PubMed
123.
Ferrari TC, Moreira PR, Cunha AS. Spinal cord schistosomiasis: a prospective study of 63 cases emphasizing clinical and therapeutic aspects. J clin neurosci off j Neurosurg Soc Aust. 2004;11(3):246–53.
124.
Moreno-Carvalho OA, Nascimento-Carvalho CM, Bacelar AL, et al. Clinical and cerebrospinal fluid (CSF) profile and CSF criteria for the diagnosis of spinal cord schistosomiasis. Arquivos de neuro-psiquiatria. 2003;61(2B):353–8.PubMed
125.
Weller PF, Liu LX. Eosinophilic meningitis. Semin neurol. 1993;13(2):161–8.PubMed
126.
Rachford FW. Potential intermediate and paratenic hosts for Angiostrongylus cantonensis. J parasitol. 1975;61(6):1117–9.PubMed
127.
Wallace GD, Rosen L. Studies on eosinophilic meningitis. IV. Experimental infection of fresh-water and marine fish with Angiostrongylus cantonensis. Am j epidemiol. 1967;85(3):395–402.PubMed
128.
Rosen L, Loison G, Laigret J, Wallace GD. Studies on eosinophilic meningitis. 3. Epidemiologic and clinical observations on Pacific islands and the possible etiologic role of Angiostrongylus cantonensis. Am j epidemiol. 1967;85(1):17–44.PubMed
129.
Ash LR. Observations on the role of mollusks and planarians in the transmission of Angiostrongylus cantonensis infection to man in New Caledonia. Rev Biol Med. 1976;24(1):163–74.
130.
Bowden DK. Eosinophilic meningitis in the New Hebrides: two outbreaks and two deaths. Am j trop med hyg. 1981;30(5):1141–3.PubMed
131.
Punyagupta S, Juttijudata P, Bunnag T. Eosinophilic meningitis in Thailand. Clinical studies of 484 typical cases probably caused by Angiostrongylus cantonensis. Am j trop med hyg. 1975;24(6 Pt 1):921–31.PubMed
132.
Kliks MM, Kroenke K, Hardman JM. Eosinophilic radiculomyeloencephalitis: an angiostrongyliasis outbreak in American Samoa related to ingestion of Achatina fulica snails. Am j trop med hyg. 1982;31(6):1114–22.PubMed
133.
Kuberski T, Wallace GD. Clinical manifestations of eosinophilic meningitis due to Angiostrongylus cantonensis. Neurology. 1979;29(12):1566–70.PubMed
134.
Kuberski T. Angiostrongyliasis. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens, and practice. 2nd ed. Philadelphia: Elsevier Churchill Livingston; 2006. p. 1225–30.
135.
Lv S, Zhang Y, Steinmann P, Zhou XN. Emerging angiostrongyliasis in Mainland China. Emerg infect dis. 2008;14(1):161–4.PubMed
136.
Kliks MM, Palumbo NE. Eosinophilic meningitis beyond the Pacific Basin: the global dispersal of a peridomestic zoonosis caused by Angiostrongylus cantonensis, the nematode lungworm of rats. Soc sci med. 1992;34(2):199–212.PubMed
137.
Slom TJ, Cortese MM, Gerber SI, et al. An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. N Engl j med. 2002;346(9):668–75.PubMed
138.
Malvy D, Ezzedine K, Receveur MC, et al. Cluster of eosinophilic meningitis attributable to Angiostrongylus cantonensis infection in French policemen troop returning from the Pacific Islands. Travel med infect dis. 2008;6(5):301–4.PubMed
139.
Graeff-Teixeira C. Expansion of Achatina fulica in Brazil and potential increased risk for angiostrongyliasis. Trans R Soc Trop Med Hyg. 2007;101(8):743–4.PubMed
140.
New D, Little MD, Cross J. Angiostrongylus cantonensis infection from eating raw snails. N Engl j med. 1995;332(16):1105–6.PubMed
141.
Markell EK, John DT, Krotoski WA. The blood– and tissue-dwelling nematodes. In: Markell EK, John DT, Krotoski WA, editors. Markell and Voge’s medical parasitology. 8th ed. Philadelphia: W.B. Saunders Compan; 1999.
142.
Punyagupta S, Bunnag T, Juttijudata P, Rosen L. Eosinophilic meningitis in Thailand. Epidemiologic studies of 484 typical cases and the etiologic role of Angiostrongylus cantonensis. Am j trop med hyg. 1970;19(6):950–8.PubMed
143.
Yii CY. Clinical observations on eosinophilic meningitis and meningoencephalitis caused by Angiostrongylus cantonensis on Taiwan. Am j trop med hyg. 1976;25(2):233–49.PubMed
144.
Moore DA, McCroddan J, Dekumyoy P, Chiodini PL. Gnathostomiasis: an emerging imported disease. Emerg infect dis. 2003;9(6):647–50.PubMed
145.
Punyagupta S, Limtrakul C, Vichipanthu P, Karnchanachetanee C, Nye SW. Radiculomyeloencephalitis associated with eosinophilic pleocytosis. Report of nine cases. Am j trop med hyg. 1968;17(4):551–60.PubMed
146.
Diaz JH. Recognizing and reducing the risks of helminthic eosinophilic meningitis in travelers: differential diagnosis, disease management, prevention, and control. J travel med. 2009;16(4):267–75.PubMed
147.
Pai PJ, Blackburn BG, Kazacos KR, Warrier RP, Begue RE. Full recovery from Baylisascaris procyonis eosinophilic meningitis. Emerg infect dis. 2007;13(6):928–30.PubMed
148.
Gavin PJ, Kazacos KR, Tan TQ, et al. Neural larva migrans caused by the raccoon roundworm Baylisascaris procyonis. Pediatr infect dis j. 2002;21(10):971–5.PubMed
149.
Cunningham CK, Kazacos KR, Mcmillan JA, et al. Diagnosis and Management of Baylisascaris-Procyonis Infection in an Infant with Nonfatal Meningoencephalitis. Clin Infect Dis. 1994;18(6):868–72.PubMed
150.
Kazacos KR, Gavin PJ, Shulman ST, et al. Raccoon roundworm encephalitis - Chicago, Illinois, and Los Angeles, California, 2000 (Reprinted from MMWR, vol 50, pg 1153, 2002). Jama-J Am Med Assoc. 2002;287(5):580–1.
151.
Park SY, Glaser C, Murray WJ, et al. Raccoon roundworm (Baylisascaris procyonis) encephalitis: case report and field investigation. Pediatrics. 2000;106(4):E56.PubMed
152.
Murray WJ, Kazacos KR. Raccoon roundworm encephalitis. Clin infect dis off publ Infect Dis Soc Am. 2004;39(10):1484–92.
153.
Nelson CA, Zunt JR. Tuberculosis of the central nervous system in immunocompromised patients: HIV infection and solid organ transplant recipients. Clin infect dis off publ Infect Dis Soc Am. 2011;53(9):915–26.
154.
Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin infect dis off publ Infect Dis Soc Am. 2010;50 Suppl 3:S223–30.
155.
Asano T, Kawamoto H, Asakuma J, Tanimoto T, Kobayashi H, Hayakawa M. Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient. Transplant proc. 2000;32(7):1960–2.PubMed
156.
Wells CD. Global Impact of Multidrug-Resistant Pulmonary Tuberculosis Among HIV-Infected and Other Immunocompromised Hosts: Epidemiology, Diagnosis, and Strategies for Management. Curr infect dis rep. 2010;12(3):192–7.PubMed
157.
Lynch K, Farrell M. Cerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment. Clin rheumatol. 2010;29(10):1201–4.PubMed
158.
Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin microbiol rev. 2012;25(2):264–96.PubMed
159.
Petersen E, Kijlstra A, Stanford M. Epidemiology of ocular toxoplasmosis. Ocul immunol inflamm. 2012;20(2):68–75.PubMed
160.
Ekman CC, Chiossi MF, Meireles LR, et al. Case–control study of an outbreak of acute toxoplasmosis in an industrial plant in the state of Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54(5):239–44.PubMed
161.
Lortholary O, Charlier C, Lebeaux D, Lecuit M, Consigny PH. Fungal infections in immunocompromised travelers. Clin infect dis off publ Infect Dis Soc Am. 2013;56(6):861–9.
162.
Norman FF, López-Vélez R. Prevention of Tropical and Parasitic Infections: The Immunocompromised Traveler. In: Safdar A, editor. Principles and Practice of Cancer Infectious Diseases. Berlin: Springer; 2011. p. 551–60.
163.
Wieten RW, Leenstra T, Goorhuis A, van Vugt M, Grobusch MP. Health risks of travelers with medical conditions–a retrospective analysis. J travel med. 2012;19(2):104–10.PubMed
164.
Chang F, Prytherch H, Nesbitt RC, Wilder-Smith A. HIV-related travel restrictions: trends and country characteristics. Global health action. 2013;6:20472.PubMed
Metadaten
Titel
Central Nervous System Infections in Travelers
verfasst von
H. L. Kirsch
K. T. Thakur
G. L. Birbeck
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 6/2013
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0383-8

Weitere Artikel der Ausgabe 6/2013

Current Infectious Disease Reports 6/2013 Zur Ausgabe

Healthcare Associated Infections (G Bearman and M Stevens, Section Editors)

Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices

CENTRAL NERVOUS SYSTEM (J LYONS, SECTION EDITOR)

Central Nervous System Tuberculosis: Challenges and Advances in Diagnosis and Treatment

Healthcare Associated Infections (G Bearman and M Stevens, Section Editors)

Challenges in Measuring Antibiotic Consumption

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis

CENTRAL NERVOUS SYSTEM (J LYONS, SECTION EDITOR)

Advances in Infectious Encephalitis: Etiologies, Outcomes, and Potential Links with Anti-NMDAR Encephalitis

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Multidrug-Resistant Bacteria in Organ Transplantation: An Emerging Threat with Limited Therapeutic Options

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise